Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/ HR- Trial

Graeser, Monika; Gluz, Oleg; Biehl, Claudia; Ulbrich-Gebauer, Daniel; Christgen, Matthias; Palatty, Jenci; Kuemmel, Sherko; Grischke, Eva -Maria; Augustin, Doris; Braun, Michael; Potenberg, Jochem; Wuerstlein, Rachel; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; zu Eulenburg, Christine; Kates, Ronald; Ni, Hua; Kolberg-Liedtke, Cornelia; Feuerhake, Friedrich; Kreipe, Hans Heinrich; Nitz, Ulrike; Harbeck, Nadia; WSG-ADAPT Investigators

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/ HR- Trial

Autor(en):

Graeser, Monika; Gluz, Oleg; Biehl, Claudia; Ulbrich-Gebauer, Daniel; Christgen, Matthias; Palatty, Jenci; Kuemmel, Sherko; Grischke, Eva -Maria; Augustin, Doris; Braun, Michael; Potenberg, Jochem; Wuerstlein, Rachel; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; zu Eulenburg, Christine; Kates, Ronald; Ni, Hua; Kolberg-Liedtke, Cornelia; Feuerhake, Friedrich; Kreipe, Hans Heinrich; Nitz, Ulrike; Harbeck, Nadia; WSG-ADAPT Investigators

Tübinger Autor(en):

Grischke, Eva-Maria

Erschienen in:

Clinical Cancer Research (2023), Bd. 29, H. 4, S. 805-814

Verlagsangabe:

Amer Assoc Cancer Research

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1158/1078-0432.CCR-22-1587

ISSN:

1078-0432